Granules India receives three observations from USFDA audit

22 Dec 2015 Evaluate

Granules India, one of the country’s leading pharmaceutical manufacturing companies has received three observations from US Food and Drug Administration (USFDA) for its Jeedimetla, Hyderabad facility during a recent inspection. USFDA has completed the inspection of company’s two facilities, one located at Vizag in Andhra Pradesh and another at Jeedimetla in Telangana, Granules India. While there were no observations received for Vizag facility, three observations were received for Jeedimetla facility. The company will respond to the observations in 15 business days.

Granules India is a fast growing pharmaceutical company with world-class facilities for APIs, PFIs and Finished Dosages, serving customers in over 60 countries. The company is headquartered in Hyderabad with offices in the U.S., U.K., Colombia and China with manufacturing facilities in India and China.

Granules India Share Price

558.90 13.45 (2.47%)
22-Nov-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1797.80
Dr. Reddys Lab 1213.90
Cipla 1486.30
Lupin 2069.95
Zydus Lifesciences 948.70
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.